DRP Director: John Leonard, MD (WCMC) Co-Director: Anas Younes (MSK) DRP SUMMARY The Developmental Research Program (DRP) will identify new opportunities to support physicians and scientists, and encourage them to use their expertise to develop novel translational research ideas in lymphoma. The DRP will provide seed funding to generate and explore new hypotheses that may subsequently be expanded and tested as full project within the Lymphoma SPORE, or through other SPORE- independent peer-reviewed external grant support. The purpose of the SPORE DRP is to develop translational research projects that should result in testable hypotheses aimed at improving the diagnosis and treatment of lymphoma. On an annual basis, a request for proposals will be distributed to all participating institutions. Selected proposals (1-2 annually) will be supported with $50,000 of the SPORE budget with matching institutional support. Funding will be awarded for 1 year. Based on accomplishments during the first year, and review by the EAB, funding may be extended by a second year. Usual NIH review criteria will be used in selection of projects. Proposals from underrepresented minority and female applicants will be specifically solicited. The program takes advantage of a strong group of investigators with documented scientific record and outstanding infrastructure at all three participating Institutions, Memorial Sloan Kettering Cancer Center (MSK), Weill-Cornell Medical College (WCMC) and the Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center.

Public Health Relevance

Non-Hodgkin lymphoma represents the 6th most common type of cancer in adults, and remains a compelling clinical problem, with approximately one third of patients not responding to currently available chemotherapeutic approaches. The general goal of the Developmental Research Program is to recruit exceptional individuals to explore novel translational research ideas focused on lymphoma that will ultimately contribute to improving the cure rate of patients with lymphoma.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA192937-01A1
Application #
8997370
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2016-08-30
Project End
2021-07-31
Budget Start
2016-08-30
Budget End
2017-07-31
Support Year
1
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Lu, Xiaoqing; Fernando, Tharu M; Lossos, Chen et al. (2018) PRMT5 interacts with the BCL6 oncoprotein and is required for germinal center formation and lymphoma cell survival. Blood 132:2026-2039
Kaittanis, Charalambos; Andreou, Chrysafis; Hieronymus, Haley et al. (2018) Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors. J Exp Med 215:159-175
Liu, Yuxuan; Mondello, Patrizia; Erazo, Tatiana et al. (2018) NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell death. Proc Natl Acad Sci U S A 115:12034-12039
Intlekofer, Andrew M; Joffe, Erel; Batlevi, Connie L et al. (2018) Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay. Blood Cancer J 8:60
Avanzi, Mauro P; Yeku, Oladapo; Li, Xinghuo et al. (2018) Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System. Cell Rep 23:2130-2141
Pasqualucci, Laura; Dalla-Favera, Riccardo (2018) Genetics of diffuse large B-cell lymphoma. Blood 131:2307-2319
Joshi, Suhasini; Wang, Tai; Araujo, ThaĆ­s L S et al. (2018) Adapting to stress - chaperome networks in cancer. Nat Rev Cancer 18:562-575
Kishinevsky, Sarah; Wang, Tai; Rodina, Anna et al. (2018) HSP90-incorporating chaperome networks as biosensor for disease-related pathways in patient-specific midbrain dopamine neurons. Nat Commun 9:4345
Rafiq, Sarwish; Yeku, Oladapo O; Jackson, Hollie J et al. (2018) Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol 36:847-856
Oricchio, Elisa; Katanayeva, Natalya; Donaldson, Maria Christine et al. (2017) Genetic and epigenetic inactivation of SESTRIN1 controls mTORC1 and response to EZH2 inhibition in follicular lymphoma. Sci Transl Med 9:

Showing the most recent 10 out of 28 publications